Are Epigral latest results good or bad?

Epigral, a midcap player in the specialty chemicals industry, has reported its financial results for the quarter ending June 2025. The key takeaway from these results indicates a mixed operational performance.
On a positive note, Epigral's Profit After Tax (PAT) reached Rs 160.69 crore, reflecting significant growth compared to the average PAT of Rs 89.42 crore from the previous four quarters, marking the highest PAT recorded in the last five quarters. Additionally, the Earnings per Share (EPS) peaked at Rs 37.25, suggesting enhanced profitability for shareholders. The company's Debt-Equity Ratio improved to 0.31 times, indicating a reduction in borrowing relative to equity capital.

However, the company also faced challenges during this period. Profit Before Tax less Other Income (PBT) fell to Rs 98.76 crore, which is the lowest in five quarters, representing a decline of 24.9%. Furthermore, net sales decreased to Rs 606.54 crore, and the Operating Profit Margin saw a decline to 26.94%. The financial results were also impacted by rising interest costs and a slowing inventory turnover ratio.

Overall, while Epigral experienced notable growth in PAT and EPS, the decline in net sales and PBT, along with the adjustment in its evaluation, highlights the complexities of its current financial landscape.